Insys Therapeutics (INSY) Misses Q3 EPS
Get Alerts INSY Hot Sheet
Join SI Premium – FREE
Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of ($0.41), $0.20 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $18.3 million versus the consensus estimate of $23.52 million.
For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- Oxford Square Capital Corp. (OXSQ) Misses Q3 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share